Episode 57
Biotech Hangout
00:00
The Balance of Single Asset Companies
Single asset companies make great emanate targets, right? So I think an acquire coming in doesn't need to find fine value in a whole pipeline. While you can do kind of like the biohaven deal where you spin out your pipeline, my understanding is that they need it to be very, very well prepared to do that spin out. And so it's not something that's easy to do in the context of a usual kind of, usual kind of emanate.
Transcript
Play full episode
